Health Discovery Corporation (OTCBB: HDVY) announced today it has been selected by MDB Capital Group as one of its Top 50 “Best and Brightest” companies that will present at the invitation-only, 1 st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property. “Health Discovery Corporation was selected to present on the basis of ranking in the 90th percentile for IP leadership from over 1,600 small cap companies with U.S. patents granted, as rated by PatentVest, MDB Capital Group’s proprietary IP intelligence platform,” said Chris Marlett, Co-Founder, Chairman and CEO of MDB Capital Group. “Health Discovery Corporation currently enjoys an impressive Tech Score of 3.93 placing the company in the Top 1% of 1,600 companies evaluated based on this metric,” said Mr. Marlett. “The primary selection metric used for Bright Lights is PatentVest’s Tech Score, a proprietary measure of the industry impact of a company’s patents based upon the analysis of patent citations relative to its peer group of patents,” said Mr. Marlett. “We have found PatentVest Tech Score to be correlated to business performance, and therefore predictive of risk-adjusted returns, over the intermediate and longer-term.” A related white paper is available from MDB Capital Group. The conference will be held May 10-12, 2010, in San Francisco. The Company has accepted the invitation. The Bright Lights Conference will be the first-ever public company conference of its kind -- a conference where small cap companies are chosen to present on the basis of their (often hidden) Intellectual Property value and potential for market-changing innovation. Institutional investors from several countries, as well as IP thought leaders, will be in attendance for the first public company conference to focus exclusively on selected companies with disruptive and market changing Intellectual property.
“MDB Capital Group should be commended for their ground-breaking methodology in analyzing the value of public companies’ intellectual property,” said Stephen D. Barnhill, Chairman and CEO, of Health Discovery Corporation. “The work done by MDB Capital validates our franchise and our pioneering leadership in the field of Support Vector Machines technology,” said Dr. Barnhill. “We gladly accepted the invitation to present at this upcoming conference,” said Dr. Barnhill.HDC Granted New Patent Health Discovery Corporation also announced that it received notification from the U.S. Patent and Trademark Office that its application entitled "Kernels and Kernel Methods for Spectral Data," will issue as Patent No. 7,676,442 on March 9, 2010. This new patent covers the use of SVMs in conjunction with a proprietary pre-processing technique to greatly improve analysis of data obtained using mass spectrometry. Mass spectrometry is widely used for chemical and biological testing and is particularly applicable to protein analysis for biomarker discovery. Protein mass spectrometry data combined with SVMs was used by Vermillion, Inc. (Other OTCBB: VRMLQ.PK) in discovery of the genes in its OVA1 ovarian cancer test, which is expected to be brought to market by Quest Diagnostics, Incorporated (NYSE: DGX) in March 2010. A continuation application based on this new patent has been filed to expand Health Discovery Corporation's coverage of the use of SVMs for analysis of many other types of spectral data. Analysis of spectral data is required in virtually any technology in which a signal is detected, including communications, optics, intelligence, aerospace, defense, regulatory monitoring, including food and water safety testing, medical diagnostics, and consumer electronics. HDC’s Patent Portfolio With the issuance of the new patent described above, HDC now holds exclusive rights to a total of 42 issued U.S. and foreign patents and 32 pending patents. HDC has a total of 74 patents pending and issued. Importantly, the earliest expiration of any of the HDC patents is May 2019, with most of the patents having terms that will provide additional protection of 5 or more years beyond that date.
About Health Discovery CorporationHealth Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings. All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.